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Dendritic cells (DCs) provide an essential link between innate and adaptive immunity. At
the site of infection, antigens recognized by DCs via pattern-recognition receptors, such
asToll-like receptors (TLRs), initiate a specific immune response. Depending on the nature
of the antigen, DCs secrete distinct cytokines with which they orchestrate homeostasis
and pathogen clearance. Dysregulation of this process can lead to unnecessary inflam-
mation, which can result in a plethora of inflammatory diseases. Therefore, the secretion
of cytokines from DCs is tightly regulated and this regulation is facilitated by highly con-
served trafficking protein families.These proteins control the transport of vesicles from the
Golgi complex to the cell surface and between organelles. In this review, we will discuss
the role of soluble n-ethylmaleimide-sensitive factor attachment protein receptor proteins
(SNAREs) in DCs, both as facilitators of secretion and as useful tools to determine the
pathways of secretion through their definite locations within the cells and inherent speci-
ficity in opposing binding partners on vesicles and target membranes.The role of SNAREs
in DC function may present an opportunity to explore these proteins as novel targets in
inflammatory disease.
Keywords: dendritic cells, SNAREs, IL-6, IL-23, IL-12
INTRODUCTION
Dendritic cells (DCs) were first described by Ralph Steinman and
Zanvil Cohn as a rare murine splenocyte with dendrite-like pro-
trusions that displayed phagocytic abilities (1). Following their
discovery, work carried out by Steinman’s group demonstrated
that DCs play a vital role in orchestrating immunity. In their
immature state in the peripheral tissue, DCs are characterized by a
high capacity for antigen capture and processing via phagocytosis.
They display distinct chemokine receptor expression, chemokine
responsiveness, and low T cell stimulatory capabilities (2). The
ability of DCs to regulate immunity is dependent on their matu-
ration, which is induced by the interaction of DCs with antigens
that are subsequently presented to T cells. During this process, DCs
secrete distinct profiles of cytokines and chemokines and express
co-stimulatory molecules required to drive specific T cell responses
(3). The control of these secretory pathways is an essential factor in
regulating innate and adaptive immune homeostasis and control-
ling responses to infection (4). In this review, we will discuss the
factors that induce DC maturation, the cytokines secreted by DCs
that drive adaptive immunity, and the secretory pathways that have
been identified and their potential as immunotherapeutic targets.
DENDRITIC CELL ACTIVATION
For maturation to occur, foreign antigens must be identified by
DCs. DCs express pattern recognition receptors (PRRs) that allow
them to recognize microbes that display pathogen-associated mol-
ecular patterns (PAMPs). PRRs can be divided into toll-like recep-
tors (TLRs), C-type lectin receptors (CLRs), nucleotide-binding
domain and leucine-rich repeat containing receptors (NLRs) and
retinoic acid-inducible gene-I (RIG)-like receptors (RLRs) (5).
Following engagement of these PRRs, signaling cascades are acti-
vated that induce the production of inflammatory cytokines (6).
Inflammatory responses can also be triggered by endogenous
damage-associated molecular patterns (DAMPs). These are intra-
cellular markers that are also recognized by PRRs, and are released
during tissue damage or when a cell is necrotic releasing intracel-
lular material into its surroundings (7). Following PRR ligation
and subsequent maturation, DCs become antigen presenting cells
(APC) (8). The mature DC travels to the local lymph node (9),
which facilitates the presentation of antigen to antigen-specific
lymphocytes to prime naive T cells to become effector T cells.
Three signals are required for this: antigen presentation, up-
regulation of co-stimulatory markers, and secretion of cytokines;
this review will focus on the third signal, cytokine secretion and
their effects (10).
CYTOKINE POLARIZATION OF T CELL SUBSETS
Clonal immunity involves DC activation of T cells through pre-
sentation of processed antigen to naïve T cells in an immunogenic
form and the secretion of immune mediators called cytokines.
Cytokines are classified into interleukins (IL), interferons (IFNs),
and colony-stimulating factors. Cytokine profiles secreted from
DCs polarize naïve T cells into different phenotypes of CD4+
T cells. These differential cytokine secretion patterns are depen-
dent on the PRR activation, and subsequently are the key signals
required for the differentiation into different T helper (Th) cell
phenotype subsets that are required to clear the antigen that trigger
the immune response (11).
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In order to clear bacterial and viral infections, naïve CD4+ T-
cells require cytokine signaling from DCs to initiate differentiation
into a Th1 phenotype. TLRs present on DCs recognize PAMPs,
such as lipopolysaccharide and unmethylated dsDNA, through
TLR4 and TLR9 respectively. Engagement of these TLRs results
in secretion of the cytokines IL-1, IL-6, TNF-α, and IL-12p40
(10). Dimerization of IL-12p40 with IL-12p35 results in an active
IL-12p70 heterodimer. IL-12p70 together with IFN-γ, which is
produced in large amounts by activated T-cells, leads to differenti-
ation of T-cells in to an IFN-γ producing Th1 cells subset (12). Th2
cells produce high levels of IL-4, IL-5,and IL-13. They are responsi-
ble for initiating the humoral immune response and are required to
clear helminth infections. Th2 cells have been generated in vitro via
stimulation of the TCR and the addition of IL-4 (13). IL-4 induces
the induction of Th2 cells via STAT6, given the fact that DCs do
not produce IL-4, the mechanisms through which Th2 cells initiate
this subset remain unclear. However, cytokine signaling from DCs
can indirectly affect the differentiation. DCs activated through
TLR2, DC-SIGN, and OSCAR (an FcγR-associated receptor) lead
to the activation of Erk1 and Erk2 pathways and phosphorylation
of c-Fos (14). This leads to the inhibition of IL-12 and increased
production of IL-10 in DCs, which is sufficient to induce a strong
Th2 response in naïve T-cells. Cytokines produced by other cells
can also influence DCs to drive a Th2 subset through chemokine
production that recruits IL-4 producing cells and the activation of
cytokine receptors (11).
Th17 cells were first described in 2006 and identified as a T
helper subset distinct from Th1 and Th2 cells that produced the
cytokine IL-17 (15). Th17 cells have been indicated to confer pro-
tection against extracellular bacteria and fungi by the secretion
of effector molecules such as IL-17, IL-21, IL-22, GM-CSF, and
CCL20 (16). However, Th17 cells have also been implicated in
many autoimmune and inflammatory diseases, such as rheuma-
toid arthritis (RA), systemic lupus erythematosus, multiple scle-
rosis, psoriasis, and inflammatory bowel disease (IBD) (17). The
conditions for differentiation of Th17 cells is more complex than
Th1 and Th2 subsets, and there is evidence to support a role for
a number of cytokines produced by DCs, including IL-1, IL-18,
IL-6, and IL-23. These cytokines are produced by DCs in response
to PRR recognition of bacteria and fungi.
In the case of Th17 differentiation, it is not just TLR-mediated
activation that promotes the secretion of these cytokines. Dectin-1
and dectin-2 activate CLRs on DCs to promote section of IL-
6 and IL-23, cytokines that play a major role in differentiating
and stabilizing the Th17 response respectively (18). T-regulatory
cells are essential for negative regulation of the immune response,
as they possess immunosuppressive abilities that confer protec-
tion to the host from autoimmunity and prevention of excessive
immunopathology. If this response becomes dysregulated, it can
lead to autoimmune disorders due to loss of homeostasis. IL-27,
IL-10, and TGF-β1 secretion by DCs have been heavily indicated
in the induction of Treg cells (19).
TARGETING CYTOKINES IN INFLAMMATORY DISEASE
Cytokines are essential in driving the adaptive immune response;
thus, targeting cytokines associated with inflammatory disease has
become a significant area for drug development (20). Indeed,
secretory pathways are attractive to study as potential targets to
block critical cytokines with the possibility of switching off inflam-
mation without any detrimental side effects (21). A number of
therapeutics currently exist that target key cytokines such as IL-23
and IL-6, which are associated with inflammatory disease.
IL-23, essential for stabilizing Th17 cells, has been implicated
in the pathogenesis of multiple sclerosis, arthritis, and IBD. Using
mouse models of diseases, the essential role of IL-23 has been
established (16, 22, 23). A human monoclonal antibody, Ustek-
inumab, has been developed and licensed to target the IL-12/23
pathway. This antibody targets the p40 subunit of IL-12 and IL-
23, and was originally developed to target IL-12 induction of Th1
cells, as IL-23 had still not yet been identified or recognized in
its function of driving Th17 differentiation. These applications
include psoriatic arthritis, multiple sclerosis, and Crohn’s disease,
and the drug has displayed good efficacy except in the case of
multiple sclerosis (24).
IL-6 has also been implicated as an important cytokine in
driving the Th17 subset. Aberrant expression of IL-6 has been
indicated in inflammatory diseases such as RA and juvenile idio-
pathic arthritis (JIA), leading to the development of a humanized
IL-6 receptor (25). Tocilizumab blocks IL-6 receptor in both sol-
uble and membrane bound forms with the result of blocking IL-6
function. In the clinic, tocilizumab has demonstrated amelioration
of inflammatory diseases such as RA and JIA with improvement in
symptoms such as joint destruction and a reduction in the number
of flare incidents in JIA (26).
SECRETION OF IMMUNE MEDIATORS
It is clear that DC cytokine release is essential and tailored to clear-
ing specific infections while also controlling immune homeostasis.
Regulation of protein trafficking and release of immune mediators
such as cytokines, chemokines, and lysosomal enzymes into the
immediate environment from DCs is therefore highly regulated
in order to prevent autoimmunity and inflammation. Indeed, a
number of mutations or deficiencies resulting in dysregulated traf-
ficking can have major implications in immune syndromes (27).
Depending on the required function of an immune mediator,
different pathways exist to transport newly synthesized proteins
out of the cell. These pathways are usually shared by a number
of factors and their release can be constant (constitutive release)
or triggered (regulated release) (4). Proteins produced in the
endoplasmic reticulum (ER) can be soluble and contained within
vesicles or membrane bound and associated within the plasma
membrane of transported vesicles.
Thus, a number of proteins share transport to the plasma mem-
brane to conserve energy (27). The release of these proteins can be
basal or dependent on their transcription at gene level in response
to cellular signaling (28).
SNARE PROTEINS
The transport of vesicles between organelles, endosomes, and the
cell surface plasma membrane is controlled by a complex network
of cellular machinery of membrane associated proteins, lipids,
and cytoplasmic proteins. Soluble-N-ethylmaleimide–sensitive
factor accessory protein receptor proteins (SNAREs) are a large
conserved family identified in the docking/fusion machinery that
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allow membranes to overcome opposing forces and fuse docked
lipid bilayers (27).
SNARE proteins are all identified by a common conserved
SNARE motif of 60–70 amino acids arranged in heptad repeats
typical for coiled coils (29). Most SNAREs are type II integral
membrane proteins that possess a single trans-membrane domain
at their carboxyl (C-terminal) end that is connected to the SNARE
motif by a flexible linker, with the majority of the protein extend-
ing into the cytoplasm (30). The conserved coiled-coil SNARE
motif is necessary for complex formation and membrane fusion
(31). When SNAREs form in a tight helical bundle, they form
a conserved structure of an elongated coiled coil of four inter-
twined α-helices that correspond to the four interacting SNARE
motifs occupying specific positions in the complex (32). There is
a highly conserved layer of interacting amino acids in the central
hydrophobic core of the helical bundle consisting of three glut-
amines and one arginine (31). Each of these contributing motifs
contributes an amino acid and their structures are divided into
sub-families used to further classify the SNARES as R-SNAREs or
Q-SNARES (33).
R-SNARES are usually found on the membrane and have argi-
nine (R) as the central functional residue in the SNARE motif.
Q-SNARES are mainly found on the target membrane and are
defined by a central glutamine (Q) residue. In order to form a
complex and mediate membrane fusion, one R-SNARE and two
or three Q-SNARE motifs are required to form a stable RQabc four
helical bundle (30, 34). The SNARE proteins on opposing mem-
branes interact to form the α-helix bundle that “zippers” together
from the N-terminus to the C-terminus forming a trans-SNARE
complex (or SNAREpin). The energy provided by the zippering
complex formation pulls the membranes together displacing the
water and hydrostatic pressure keeping them apart, thereby facili-
tating the mixing of hydrophobic lipids (35). Once the membranes
have fused, the trans-SNARE conformation is converted to a
highly stable inert cis-SNARE conformation on the resulting fused
membrane. In order to dissociate this stable structure, metabolic
energy is required and this is provided by two chaperone pro-
teins; N -ethylmaleimide-sensitive factor (NSF), and Soluble NSF
attachment protein (SNAP) (36, 37). This dissociation facilitates
the recycling of SNARE proteins and prevents accumulation of
SNAREs on the membrane. Many SNAREs operate predominantly
in a specific subcellular compartment with their partners and some
Qa SNAREs such as Syntaxin (STX)2 and STX4 are found on the
plasma membrane and involved in fusion of vesicles and secretion
of their contents from the cell. Other Qa SNAREs including STX5
and the R-SNARE vesicle-associated membrane protein (VAMP)4
are localized in the Golgi apparatus (38). These SNAREs are there-
fore found in the membranes of the donor compartment, acceptor
compartment, and the intermediate trafficking vesicles (39).
THE ROLE OF SNAREs IN DENDRITIC CELLS
As the immune system consists of a plethora of cells that have
specific functions, an understanding of the mechanism of traf-
ficking is extremely important for when these functions become
dysregulated and lead to disease. Cytokine signaling from DCs,
in particular, is one of the most important types of signaling for
the regulation of the adaptive immune response. However, while
the role of SNAREs in secretion of key immune mediators has
been addressed in many immune cells, the role of SNAREs in
DCs function is poorly understood. Examples of SNAREs regulat-
ing critical function in other immune cells include STX11 which
has been implicated in neutrophil degranulation and interferon-
γ (IFN-γ) secretion from natural killer cells (40). Inhibition of
SNAP23 or STX3 abolished chemokine release from mast cells
and has been attributed to STX11. (41). While these individual
SNAREs and their function have been identified in these cell types,
a full elucidation of these trafficking pathways and/or SNARE
partners have yet to be identified. However, in the last 10 years,
Stow and colleagues have mapped the secretion of TNF-α from
macrophages and fully elucidated an original secretion pathway
through recycling endosomes that is implicitly linked to their
phagocytic activity (42–44).
Furthermore, loss of STX11 in macrophages resulted in
increased phagocytosis and TNF-α secretion, suggesting that this
SNARE plays its part as a negative regulator (45). This hypothesis is
supported in patients with the hyper-inflammatory disease, famil-
ial hemophagocytic lymphohistiocytosis type 4 (FHL-4), which
results from a deletion or a mutation in STX11 (46). These patients
possess high levels of pro-inflammatory cytokines (IFN-γ, IL-6,
TNF-α, and IL-18) and have a higher number of macrophages that
become over-activated and have increased phagocytic activity (47,
48). From their findings in macrophage, Offenhäuser et al. (45)
accredited STX11’s regulatory ability due to it how it binds and
inhibits other SNARE proteins via its conserved SNARE sequence
and lack of a trans-membrane domain (45). A role for STX11 in
regulation of DCs has also been suggested. STX11 was examined
in Bone marrow-derived dendritic cells (BMDCs) by D’Orlando
et al. (40), and it was reported that although mRNA levels were
up-regulated in BMDCs, STX11 deficiency did not affect BMDC
activities or TLR-induced secretion of IL-12, IL-6, or TNF-α (41).
Work by our own group, in a paper published in this issue of Fron-
tiers, shows a correlation of up-regulation of STX11 expression in
BMDCs in response to TLR ligands. Further work is required to
confirm the role of STX11 in DCs although it is possible that the
role of STX11 in phagocytic APCs is conserved (49).
VAMP8 is an R-SNARE that has also been reported to sig-
nificantly inhibit phagocytosis in DCs (50). In this study, the
authors show that VAMP8 associates with lysosome-associated
membrane protein-2 (LAMP2) at the phagosome in dendritic
cells, following bacterial exposure. Use of VAMP8-/- DCs signifi-
cantly increased phagocytic ability. Furthermore, over-expression
of VAMP8 in a DC2.4 cell line inhibited phagocytosis. Ho et al.
also suggest that VAMP7 also negatively regulates phagocyto-
sis in the same manner, as both VAMP7 and VAMP8 can form
SNARE complexes with STX7, STX8, and Vti1b (50). This com-
plex has been show to mediate homotypic fusion of early and late
endosomes (51).
SNARE expression in DC has been reported in some detail in a
paper describing differential expression following treatment with
acetylsalicylic acid (ASA), the active ingredient in aspirin. Cai et al.
reported that SNARE expression of Vti1a, Vti1b, VAMP3, VAMP8,
and STX8 were all up-regulated following treatment with ASA
(52). The authors describe a decrease in phagocytosis in response
to ASA, and attribute it to the up-regulation of Vti1a and Vti1b
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on phagosomes, and inhibition of SNARE complex formation.
This study also describes the up-regulation of VAMP8 in cells that
have decreased phagocytic ability, corroborating the findings by
Ho et al. (50). Vti1b can also form a SNARE complex with VAMP
8 in the previously described STX7/STX8/Vti1b SNARE complex
identified on endosomal membranes (51).
Cross-presentation is another essential function of DCs that is
regulated by SNARE proteins. Sec22b was identified by Cebrian
et al. (2011) as a specific regulator of cross-presentation. Sec22b is
localized to the ER-Golgi intermediate compartment which inter-
acts with STX4 on the phagosome. In the absence of Sec22b, DCs
were unable to transfer antigen from phagosomes to the cytosol
and degradation of the antigen in the phagosome increased (53).
It was recently shown that while Sec22b-mediated phagosomal
recruitment is required for cross presentation, it is independent of
TLR signaling and cannot deliver MHC class I (MHC-I). Nair-
Gupta et al. have shown that large quantities of MHC-I are
stored in the endosomal recycling compartment (ERC) (which
possess Rab11a, VAMP3, and VAMP8 on its surface). TLR signal-
ing through the myeloid differentiation (MyD) marker, MyD88,
results in phosphorylation of SNAP-23 present on the phagosome.
This leads to stabilization of SNARE complexes, fusion of ERC
and the phagosome, and ultimately cross-presentation (54). These
findings regarding cross-presentation are summarized in Figure 1.
Work in our own group is currently identifying the mechanisms
of secretion of key immune mediators involved in inflammatory
FIGURE 1 |The as yet unknown side of DC secretion post-TLR
activation, and trafficking molecules currently identified in DC function.
Following TLR activation with TLR ligands, such as LPS, DCs activate
intracellular pathways that lead to the transcription of inflammatory
mediators, such as cytokines. While this pathway is extremely well defined
(black arrows), very little is known of the post-transcriptional pathway and
how proteins, in particular cytokines, are trafficked out of the DC. It is
evident from other cell types that SNARE proteins play a role in secretion of
cytokines; however, to date, their specific role has not yet been described.
SNARE importance in DCs has been highlighted by studies that
demonstrate that STX4 on the phagosome interacts with Sec22b on the
ER-Golgi intermediate compartment, which is required for
cross-presentation and MyD88-dependent TLR signaling, and results in
phosphorylation of SNAP23 present on the phagosome. This leads to fusion
with endosomal recycling compartment (ERC) and ultimately
cross-presentation. Furthermore, VAMP8 has been shown to be a negative
regulator of phagocytosis (red arrows). Our recent work has indicated a role
for STX3 in IL-6 and possibly MIP1-α secretion (green arrows). This work and
others also suggests a role for STX11 in DC function as it is highly
up-regulated post TLR2, TLR4, and TLR7 activation.
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disease and we have recently identified a role for STX4 in IgE
secretion from plasma cells (55). Due to the role of DCs in the
direction of adaptive immune responses via secretion of cytokines,
we aim to elucidate these pathways in detail in these cells. Another
finding from the research paper published in this issue of Frontiers,
we have described the effects of different TLR ligands on DCs and
measured the cytokine profiles secreted by these cells and their
concurrent SNARE expression (49). Specific TLR pathway activa-
tion allows DCs to respond as needed to specific challenges. For
example, when TLR4 is activated by lipopolysaccharide (LPS), this
in turn activates DCs to produce the cytokines necessary to orches-
trate an adaptive immune response to clear a bacterial infection, as
described above. Depending on the TLR agonist stimulation, dif-
ferent cytokine profiles are secreted by DC, and we demonstrate
that these profiles correlate to differential expression of SNAREs.
Assessing the secretion of cytokines from JAWSII DC’s follow-
ing activation with TLR ligands revealed that IL-6 and MIP-1α
secretion was significantly increased following stimulation with
LPS (TLR4) and Loxoribrine (TLR7) but not PGN (TLR2). This
correlated with a change in expression of STX3. Furthermore,
knockdown of STX3 using siRNA against STX3 resulted in a sig-
nificant decrease in IL-6 and MIP-1α secretion with no effect on
IL-1β or TNF-α, indicating a role for STX3 in IL-6 secretion. To
our knowledge, this is the first study to profile SNARE expres-
sion patterns following different TLR stimulations in DCs and
demonstrates the correlation between cytokine secretion patterns
and expression of SNAREs (49). This is overviewed in Figure 1,
indicated by the green arrows.
CONCLUSION
Identifying specific SNARE complexes and their regulators will
lead to a better understanding of DC function during inflam-
mation and may present potential therapeutic targets in a wide
range of inflammatory diseases. Current therapeutic monoclonal
antibodies target aberrant and subsequent damaging cytokine
production by blocking their activities. It is well known that pre-
vention is better than a cure and the current therapeutic strategies
do not meet this requirement, highlighting the need for more tar-
geted therapies. Monoclonal antibodies treatments are also prone
to off-target effects such as drug induced liver damage and the
generation of anti-idiotypic antibodies, rendering them ineffective
(56). While a number of combined antibody therapies and person-
alized medicine methodologies are being investigated, targeting
trafficking proteins and pathways to inhibit cytokine release from
the cell may prove to be a more effective therapeutic approach.
REFERENCES
1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lym-
phoid organs of mice: i Morphology, quantitation, tissue distribution. J Exp Med
(1973) 137:1142–62. doi:10.1084/jem.137.5.1142
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature
(1998) 392:245–52. doi:10.1038/32588
3. Scott K, Manunta M, Germain C, Smith P, Jones M, Mitchell P, et al. Qualitatively
distinct patterns of cytokines are released by human dendritic cells in response
to different pathogens. Immunology (2005) 116(2):245–54. doi:10.1111/j.1365-
2567.2005.02218.x
4. Lacy P, Stow JL. Cytokine release from innate immune cells: association with
diverse membrane trafficking pathways. Blood (2011) 118(1):9–18. doi:10.1182/
blood-2010-08-265892
5. Creagh EM, O’Neill LAJ. TLRs, NLRs and RLRs: a trinity of pathogen sen-
sors that co-operate in innate immunity. Trends Immunol (2006) 27:352–7.
doi:10.1016/j.it.2006.06.003
6. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recog-
nition of commensal microflora by toll-like receptors is required for intestinal
homeostasis. Cell (2004) 118:229–41. doi:10.1016/j.cell.2004.07.002
7. Zhang Q, Kang R, Zeh HJ, Lotze MT, Tang D. DAMPs and autophagy: cellular
adaptation to injury and unscheduled cell death. Autophagy (2013) 9:451–8.
doi:10.4161/auto.23691
8. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikainen S, Julkunen I, et al. Dis-
tinct patterns and kinetics of chemokine production regulate dendritic cell func-
tion. Eur J Immunol (1999) 29:1617–25. doi:10.1002/(SICI)1521-4141(199905)
29:05<1617::AID-IMMU1617>3.0.CO;2-3
9. Chan VW, Kothakota S, Rohan MC, Panganiban-Lustan L, Gardner JP, Wachow-
icz MS, et al. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for
mature dendritic cells. Blood (1999) 93:3610–6.
10. Walsh KP, Mills KHG. Dendritic cells and other innate determinants of
T helper cell polarisation. Trends Immunol (2013) 34:521–30. doi:10.1016/j.it.
2013.07.006
11. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce
T(H)2 and tolerogenic responses. Nat Immunol (2010) 11(8):647–55. doi:10.
1038/ni.1894
12. Schulz EG, Mariani L, Radbruch A, Höfer T. Sequential Polarization and
Imprinting of Type 1 T Helper lymphocytes by Interferon-3 and Interleukin-12.
Immunity (2009) 30:673–83. doi:10.1016/j.immuni.2009.03.013
13. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediat-
ing responses to IL-4 and for the development of Th2 cells. Immunity (1996)
4:313–9. doi:10.1016/S1074-7613(00)80439-2
14. Dillon S,Agrawal A,Van Dyke T, Landreth G,McCauley L,Koh A,et al. A Toll-like
receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular
signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic
cells. J Immunol (2004) 172:4733–43. doi:10.4049/jimmunol.172.8.4733
15. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YY-HH, et al. A distinct
lineage of CD4 T cells regulates tissue inflammation by producing interleukin
17. Nat Immunol (2005) 6:1133–41. doi:10.1038/ni1261
16. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein
RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in
joint autoimmune inflammation. J Exp Med (2003) 198:1951–7. doi:10.1084/
jem.20030896
17. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev
Immunol (2009) 27:485–517. doi:10.1146/annurev.immunol.021908.132710
18. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, et al. A vali-
dated regulatory network for Th17 cell specification. Cell (2012) 151:289–303.
doi:10.1016/j.cell.2012.09.016
19. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of dif-
ferentiation and function. Annu Rev Immunol (2012) 30:531–64. doi:10.1146/
annurev.immunol.25.022106.141623
20. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines
in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev
(2008) 19:41–52. doi:10.1016/j.cytogfr.2007.10.004
21. Macdonald TT. New cytokine targets in inflammatory bowel disease. Gastroen-
terol Hepatol (N Y) (2011) 7:474–6.
22. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, et al. Interleukin-23
rather than interleukin-12 is the critical cytokine for autoimmune inflammation
of the brain. Nature (2003) 421:744–8. doi:10.1038/nature01355
23. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, et al.
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp
Med (2006) 203:2473–83. doi:10.1084/jem.20061099
24. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al.
Therapeutic targeting of the IL-12/23 pathways: generation and characterization
of ustekinumab. Nat Biotechnol (2011) 29:615–24. doi:10.1038/nbt.1903
25. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody,
tocilizumab. Handb Exp Pharmacol (2008) 181:151–60. doi:10.1007/978-3-540-
73259-4_7
26. Frampton JE. Tocilizumab: a review of its use in the treatment of juvenile
idiopathic arthritis. Paediatr Drugs (2013) 15:515–31. doi:10.1007/s40272-013-
0053-1
27. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs
in the immune system. Nat Rev Immunol (2006) 6:919–29. doi:10.1038/nri1980
www.frontiersin.org March 2015 | Volume 6 | Article 133 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collins et al. A role for SNAREs in dendritic cells
28. Kioumourtzoglou D, Gould GW, Bryant NJ. Insulin stimulates Syntaxin4
SNARE complex assembly via a novel regulatory mechanism. Mol Cell Biol
(2014) 34(7):1271–9. doi:10.1128/MCB.01203-13
29. Benado A, Nasagi-Atiya Y, Sagi-Eisenberg R. Protein trafficking in immune cells.
Immunobiology (2009) 214:403–21. doi:10.1016/j.imbio.2008.11.011
30. Jahn R, Scheller RH. SNAREs - engines for membrane fusion. Nat Rev Mol Cell
Biol (2006) 7:631–43. doi:10.1038/nrm2002
31. Jahn R, Südhof TC. Membrane fusion and exocytosis. Annu Rev Biochem (1999)
68:863–911. doi:10.1146/annurev.biochem.68.1.863
32. Fasshauer D. Structural insights into the SNARE mechanism. Biochim Biophys
Acta (2003) 1641(2–3):87–97. doi:10.1016/S0167-4889(03)00090-9
33. Fasshauer D, Sutton RB, Brunger AT, Jahn R. Conserved structural features of
the synaptic fusion complex: SNARE proteins reclassified as Q- and R-SNAREs.
Proc Natl Acad Sci USA (1998) 95(26):15781–6. doi:10.1073/pnas.95.26.15781
34. Stow JL, Murray RZ. Intracellular trafficking and secretion of inflammatory
cytokines. Cytokine Growth Factor Rev (2013) 24:227–39. doi:10.1016/j.cytogfr.
2013.04.001
35. Sutton RB, Fasshauer D, Jahn R, Brunger AT. Crystal structure of a SNARE com-
plex involved in synaptic exocytosis at 2.4 angstrom resolution. Nature (1998)
395:347–53. doi:10.1038/26412
36. Bock JB, Matern HT, Peden AA, Scheller RH. A genomic perspective on
membrane compartment organization. Nature (2001) 409:839–41. doi:10.1038/
35057024
37. Block MR, Rothman JE. Purification of N-ethylmaleimide-sensitive fusion pro-
tein. Methods Enzymol (1992) 219:300–9. doi:10.1016/0076-6879(92)19030-A
38. Clary DO, Rothman JE. Purification of soluble N-ethylmaleimide-sensitive
fusion attachment proteins from bovine brain microsomes. Methods Enzymol
(1992) 219:319–30. doi:10.1016/0076-6879(92)19032-2
39. Hong W. SNAREs and traffic. Biochim Biophys Acta (2005) 1744:120–44.
doi:10.1016/j.bbamcr.2005.03.014
40. D’Orlando O, Zhao F, Kasper B, Orinska Z, Mueller J, Hermans-Borgmeyer I,
et al. Syntaxin 11 is required for NK and CD8(+) T-cell cytotoxicity and neu-
trophil degranulation. Eur J Immunol (2013) 43(1):194–208. doi:10.1002/eji.
201142343
41. Frank SPC, Thon K, Bischoff SC, Lorentz A. SNAP-23 and syntaxin-3 are
required for chemokine release by mature human mast cells. Mol Immunol
(2011) 49(1–2):353–8. doi:10.1016/j.molimm.2011.09.011
42. Pagan JK, Wylie FG, Joseph S, Widberg C, Bryant NJ, James DE, et al. The
t-SNARE syntaxin 4 is regulated during macrophage activation to function
in membrane traffic and cytokine secretion. Curr Biol (2003) 13(2):156–60.
doi:10.1016/S0960-9822(03)00006-X
43. Murray RZ, Kay JG, Sangermani DG, Stow JL. A role for the phagosome
in cytokine secretion. Science (2005) 310(5753):1492–5. doi:10.1126/science.
1120225
44. Murray RZ, Wylie FG, Khromykh T, Hume DA, Stow JL. Syntaxin 6 and Vti1b
form a novel SNARE complex, which is up-regulated in activated macrophages
to facilitate exocytosis of tumor necrosis factor-alpha. J Biol Chem (2005)
280(11):10478–83. doi:10.1074/jbc.M414420200
45. Offenhäuser C, Lei N, Roy S, Collins BM, Stow JL, Murray RZ. Syntaxin 11 binds
Vti1b and regulates late endosome to lysosome fusion in macrophages. Traffic
(2011) 12:762–73. doi:10.1111/j.1600-0854.2011.01189.x
46. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage
of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome
6q24 and identification of mutations in syntaxin 11. Hum Mol Genet (2005)
14:827–34. doi:10.1093/hmg/ddi076
47. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur
J Pediatr (2007) 166:95–109. doi:10.1007/s00431-006-0258-1
48. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu
Rev Med (2012) 63:233–46. doi:10.1146/annurev-med-041610-134208
49. Collins LE, DeCourcey J, Rochfort KD, Kristek M, Loscher CE. A role for syntaxin
3 in the secretion of IL-6 from dendritic cells following activation of toll-like
receptors. Front Immunol (2015) 5:691. doi:10.3389/fimmu.2014.00691
50. Ho YHS, Cai DT, Wang C-C, Huang D, Wong SH. Vesicle-associated membrane
protein-8/endobrevin negatively regulates phagocytosis of bacteria in dendritic
cells. J Immunol (2008) 180:3148–57. doi:10.4049/jimmunol.180.5.3148
51. Wade N, Bryant NJ, Connolly LM, Simpson RJ, Luzio JP, Piper RC, et al. Syntaxin
7 complexes with mouse Vps10p tail interactor 1b, syntaxin 6, vesicle-associated
membrane protein (VAMP)8, and VAMP7 in b16 melanoma cells. J Biol Chem
(2001) 276(23):19820–7. doi:10.1074/jbc.M010838200
52. Cai DT, Ho YHS, Chiow KH, Wee SH, Han Y, Peh MT, et al. Aspirin regulates
SNARE protein expression and phagocytosis in dendritic cells. Mol Membr Biol
(2011) 28:90–102. doi:10.3109/09687688.2010.525756
53. Cebrian I, Visentin G, Blanchard N, Jouve M, Bobard A, Moita C, et al. Sec22b
regulates phagosomal maturation and antigen crosspresentation by dendritic
cells. Cell (2011) 147:1355–68. doi:10.3109/09687688.2010.525756
54. Nair-Gupta P, Baccarini A, Tung N, Seyffer F, Florey O, Huang Y, et al.
TLR signals induce phagosomal MHC-I delivery from the endosomal recy-
cling compartment to allow cross-presentation. Cell (2014) 158(3):506–21.
doi:10.1016/j.cell.2014.04.054
55. Rahman A, DeCourcey J, Ben Larbi N, Loughran ST, Walls D, Loscher CE.
Syntaxin-4 is essential for IgE secretion by plasma cells. Biochem Biophys Res
Commun (2013) 440:163–7. doi:10.1016/j.bbrc.2013.09.058
56. Nanau RM, Neuman MG. Safety of anti-tumor necrosis factor therapies in
arthritis patients. J Pharm Pharm Sci (2014) 17:324–61.
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 24 September 2014; accepted: 10 March 2015; published online: 31 March
2015.
Citation: Collins LE, DeCourcey J, Soledad di Luca M, Rochfort KD and Loscher CE
(2015) An emerging role for SNARE proteins in dendritic cell function. Front. Immunol.
6:133. doi: 10.3389/fimmu.2015.00133
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2015 Collins, DeCourcey, Soledad di Luca, Rochfort and Loscher. This is
an open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Molecular Innate Immunity March 2015 | Volume 6 | Article 133 | 6
